Stockscreener 앱 받기
5.84
5.80%
0.32
Armata Pharmaceuticals Inc 주식(ARMP)의 최신 뉴스
Armata (ARMP) Today: Finishes 12.82% Lower at $4.42; Chart View: Price Remains Between $4.20 Support and $4.64 Resistance in the Available RecordLow Volatility Picks - vinanet.vn
Armata (ARMP) Earnings Report: EPS Falls Short of Its Estimate on the Day; Investor Response: The Market Price Advances 11.18%Earnings Preview - vinanet.vn
Madison Asset Management LLC Buys New Position in Armata Pharmaceuticals, Inc. $ARMP - MarketBeat
Armata (ARMP) Earnings Review: The EPS Result Is Below Expectation under the Current Snapshot; Post-Report Move: Shares Rise 1.79%Return On Equity - vinanet.vn
HC Wainwright Forecasts Armata Pharmaceuticals Q3 Earnings - MarketBeat
Armata Pharmaceuticals, Inc. Revenue Breakdown – AMEX:ARMP - TradingView
H.C. Wainwright Maintains Armata Pharmaceuticals(ARMP.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Armata Pharma earnings beat by $0.17, revenue topped estimates - Investing.com
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Issues Quarterly Earnings Results, Beats Expectations By $0.21 EPS - MarketBeat
Is Armata Pharmaceuticals Inc (ARMP) Facing Challenges After Q2 - GuruFocus
Armata Pharmaceuticals, Inc. 2026: Revenue $2.51M, Net income $74.14M, EPS ($0.27) — 10-Q Summary - TradingView
Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update - PR Newswire
ARMP Q1 2026 Earnings: Deep EPS Miss and No Revenue Spotlight Clinical-Stage Cash BurnGuidance Revision Trend - Vinanet
[ARMP] Q1 2026 Earnings: Clinical-Stage Biotech Reports Wider-than-Expected Net LossQuarterly Financial Update - vinanet.vn
Armata Pharmaceuticals (ARMP) Dips 2% as Shares Approach Key Support at $4.37Breakout Confirmation - vinanet.vn
Armata Pharmaceuticals (ARMP) Slips 5% as Biotech Volatility Weighs on Clinical-Stage StockTriple EMA - dars.gov.et
Armata Pharmaceuticals, Inc. Actuals & Estimates (AMEX:ARMP) - TradingView
Armata Pharmaceuticals Inc. (ARMP) Q1 2026 Earnings: Net Loss Wide of Estimates, Cash Burn Remains a FocusEPS Miss Report - dars.gov.et
Armata Pharmaceuticals Inc. (ARMP) Q1 2026 Earnings: Wider-than-Expected Loss Intensifies Investor CautionPost-Announcement Reaction - dars.gov.et
ARMP|Armata Pharmaceuticals Inc|Price:5.150|Chg%:+0.490 - TradingKey
Armata Pharmaceuticals Inc - TradingKey
Armata Pharmaceuticals Inc (ARMP) Cash Flow - TradingKey
TradingKey - TradingKey
Armata Pharmaceuticals Inc (ARMP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ARMP|Armata Pharmaceuticals Inc|Price:4.650|Chg%:-0.570 - TradingKey
Armata Pharmaceuticals Inc (ARMP) Institutional Confidence - TradingKey
Daniel B. Gilmer Net Worth (2026) - GuruFocus
Armata Pharmaceuticals, Inc. (ARMP) stock price, news, quote and history - Yahoo Finance Singapore
Armata Pharmaceuticals, Inc. (ARMP) Stock Price, News, Quote & History - Yahoo! Finance Canada
ARMATA PHARMACEUTICALS INC (ARMP) Stock Chart - ChartMill
Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA) and Armata Pharmaceuticals (ARMP) - The Globe and Mail
Armata Pharmaceuticals (ARMP) Stock Jumps 12.2%: Will It Continue to Soar? - Yahoo! Finance Canada
Armata Pharmaceuticals (ARMP) Advances Towards Phase 3 Study for AP-SA02 - GuruFocus
Armata Pharmaceuticals (ARMP) Advances Superbug Therapy, Stock R - GuruFocus
Armata (ARMP) Names David House as New CFO to Lead Financial Str - GuruFocus
Armata Shares Surge on Progress Toward Late-Stage Trial of Superbug Treatment - Moomoo
Armata submits Phase 3 protocol for antibiotic-resistant drug By Investing.com - Investing.com Nigeria
Armata Pharmaceuticals Names David House as CFO; Advances Staphylococcus Aureus Treatment Candidate - Moomoo
Why Is Armata Pharma Stock Gaining Monday? - Benzinga
Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02 - Morningstar
Armata Advances AP-SA02 Toward Phase 3 Trial Launch - TipRanks
Armata Pharmaceuticals Promotes David House to CFO - TipRanks
Armata submits Phase 3 protocol for antibiotic-resistant drug - Investing.com
Armata Pharmaceuticals: Promising Phage Platform, But Phase 3 Is Everything (NYSE:ARMP) - Seeking Alpha
Form 4 Armata Pharmaceuticals Inc For: 14 July By Investing.com - Investing.com Nigeria
Armata Pharmaceuticals (ARMP) CEO reports tax withholding of 14,041 shares - Stock Titan
Armata Pharmaceuticals, Inc. (ARMP) has received acceptance from the U.S. Food and Drug Administration (FDA) on its initial pediatric study plan for AP-SA02 for the treatment of complicated Staphylococcus aureus bacteremia. - Bitget
Armata receives FDA agreement on pediatric study plan for AP-SA02 - Investing.com UK
Armata Advances AP-SA02 Pediatric Plan With FDA Agreement - TipRanks
Armata Pharmaceuticals (ARMP) Secures FDA Agreement for Pediatri - GuruFocus
Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia - PR Newswire
FDA backs pediatric study framework for Armata’s Staph infection therapy AP-SA02 - Stock Titan
Armata Pharmaceuticals (ARMP) Trades Slightly Lower as Price Nears Key SupportETF Liquidity - DonanımHaber
Armata Pharmaceuticals, Inc.(NYSEAM:ARMP) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Armata Pharmaceuticals, Inc.(NYSEAM: ARMP) added to Russell 2500 Growth Benchmark - marketscreener.com
Armata Pharmaceuticals, Inc.(NYSEAM: ARMP) added to Russell 2000 Index - marketscreener.com
Armata Pharmaceuticals, Inc.(NYSEAM:ARMP) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Armata Pharmaceuticals, Inc.(NYSEAM: ARMP) added to Russell 3000E Growth Benchmark - marketscreener.com
Armata Pharmaceuticals, Inc.(NYSEAM: ARMP) added to Russell 3000E Index - marketscreener.com
Armata Pharmaceuticals, Inc.(NYSEAM:ARMP) added to Russell Small Cap Completeness Index - marketscreener.com
Enterprise value to EBITDA forward of Armata Pharmaceuticals, Inc. – AMEX:ARMP - TradingView
0.86%
0.31%
자본화:
|
볼륨(24시간):